8-K: Clarivate Reports Q2 2026 Results, Reaffirms Outlook

Clarivate Plc announced its second quarter 2026 financial results, reporting a net loss of $268.6 million, primarily due to a significant non-cash goodwill impairment charge, while reaffirming its full-year financial outlook.

Summary

• Clarivate reported second quarter 2026 results with total revenues of $587.3 million, a decrease from $621.4 million in Q2 2025, largely due to divestitures.
• Organic revenues decreased by 1.5%, with organic subscription growth of 0.7% offset by lower transactional revenues.
• The company reported a net loss of $268.6 million ($0.42 per diluted share) for the quarter, compared to a net loss of $72.0 million ($0.11 per diluted share) in Q2 2025, primarily driven by a $221.7 million non-cash goodwill impairment charge.
• Adjusted net income was $123.1 million ($0.19 per diluted share), a slight decrease from $123.3 million ($0.18 per diluted share) in the prior year quarter.
• Adjusted EBITDA was $247.2 million, down from $261.6 million in Q2 2025.
• For the first half of 2026, total revenues were $1,172.8 million, and the net loss was $308.8 million.
• Adjusted net income for the first half was $242.4 million, and Adjusted EBITDA was $488.4 million.
• The company reaffirmed its full-year 2026 financial outlook, including ACV organic growth of 2.0% to 3.0% and Adjusted EBITDA between $980 million and $1.04 billion.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to the significant net loss driven by an impairment charge, despite the reaffirmation of the financial outlook and strategic progress on divestitures.

Positives

• Organic ACV grew 1.5% compared to June 30, 2025, indicating progress towards a subscription-led revenue base.
• Adjusted net income for the first half of 2026 increased by 10.6% to $242.4 million compared to the prior year period.
• Adjusted diluted EPS for the first half of 2026 increased by 18.8% to $0.38.
• The company reaffirmed its full-year 2026 financial outlook, demonstrating confidence in future performance.
• The Life Sciences & Healthcare segment divestiture is expected to sharpen strategic focus and enhance the financial profile.
• Pro forma recurring revenue mix is expected to increase from 89% to approximately 92% after the LS&H divestiture.
• The company plans to use net proceeds from the LS&H divestiture to accelerate debt paydown, aiming to retire approximately $500 million of notes.

Negatives

• Total revenues decreased by 5.5% in Q2 2026 to $587.3 million compared to $621.4 million in Q2 2025, primarily due to inorganic divestitures.
• Organic revenues decreased by 1.5% in Q2 2026.
• Net loss for Q2 2026 was $268.6 million, a significant increase from a net loss of $72.0 million in Q2 2025, driven by a $221.7 million goodwill impairment charge.
• Adjusted EBITDA decreased by 5.5% in Q2 2026 to $247.2 million from $261.6 million in Q2 2025.
• Net cash provided by operating activities decreased by 15.1% in Q2 2026 to $98.7 million.
• Free cash flow decreased by 12.5% in Q2 2026 to $44.0 million.
• Total debt outstanding remains substantial at $4,251.5 million as of June 30, 2026.

Risks

• The company faces risks related to its ability to compete in a highly competitive industry.
• There is a risk associated with maintaining high annual renewal rates for subscriptions.
• Failure to keep pace with or adapt to rapidly changing technology, evolving industry standards, and changing regulatory requirements poses a risk.
• Reductions in customers' research budgets or government funding could negatively impact revenue.
• The success of the Value Creation Plan is a key factor for future performance.
• Risks associated with deriving full anticipated benefits from acquisitions, joint ventures, investments, or dispositions.
• Exposure to risk from the international scope of operations.
• Significant disruptions or unauthorized access to computer systems or breaches of data could occur.

Future Outlook

Clarivate reaffirms its full-year 2026 outlook, projecting ACV organic growth between 2.0% and 3.0%, recurring organic revenue growth of 0.75% to 2.25%, Adjusted EBITDA between $980 million and $1.04 billion, and Free Cash Flow between $365 million and $435 million. The outlook assumes no further acquisitions or divestitures and that the Life Sciences & Healthcare segment divestiture closes by year-end.

Management Comments

• "The Value Creation Plan continues to drive meaningful progress, as we execute against our strategic priorities and strengthen Clarivates foundation for organic growth acceleration."
• "During the quarter, we expanded organic recurring revenue, advanced our AI innovation roadmap, maintained disciplined cost management, and strengthened our balance sheet through deleveraging."
• "Our second quarter results reflect continued financial discipline and execution."
• "In the first half of 2026, we expanded our profit margin and reduced debt by more than $200 million through strong free cash flow generation and opportunistic debt repurchases."
• "Combined with our reaffirmed full-year outlook, these results demonstrate the resilience of our business model and our commitment to strengthening Clarivates financial profile while maintaining the flexibility to invest in our highest-value growth opportunities."

Industry Context

StockSavvy.ai notes that Clarivate's focus on AI innovation, particularly in Academia & Government with Web of Science Research Intelligence and Nexus Connect, and in Intellectual Property with IPOne, aligns with broader industry trends of leveraging AI to enhance data analysis and workflow efficiency. The divestiture of the Life Sciences & Healthcare segment signals a strategic move towards a more focused business model, a common theme among diversified information service providers seeking to unlock value and improve operational agility.

Comparison to Industry Standards

• The reported Adjusted EBITDA margin of 42.1% for Q2 2026 is within the company's full-year outlook range of 42.0% to 43.5%, suggesting performance is in line with internal expectations.
• The organic revenue decline of 1.5% in Q2 2026 is a key metric to monitor against industry peers in the data and analytics sector, which are experiencing varied growth rates depending on their specific market focus and AI integration strategies.
• The company's strategy to increase its recurring revenue mix to ~92% post-divestiture is a positive indicator, as higher recurring revenue is generally favored by investors for its predictability and stability, a benchmark for subscription-based businesses.
• The valuation multiple of 10x 2026E Adjusted EBITDA less capex for the LS&H divestiture is noted as a 'highly accretive multiple' and a '3 turn premium' to Clarivate's implied valuation, suggesting favorable deal terms compared to the company's own market valuation.

Management Changes

Stakeholder Impact

• Shareholders: The divestiture of the Life Sciences & Healthcare segment and debt reduction efforts are aimed at creating long-term shareholder value. The significant net loss due to impairment may cause short-term concern.
• Employees: The Value Creation Plan and AI innovation initiatives may lead to shifts in roles and responsibilities. The appointment of a new CFO signals a focus on financial strategy.
• Creditors: The company's commitment to debt reduction, including using divestiture proceeds, is positive for creditors, aiming to strengthen the balance sheet.

Next Steps

• Complete the divestiture of the Life Sciences & Healthcare segment, expected by the end of 2026.
• Continue executing the Value Creation Plan to drive organic growth and improve profitability.
• Invest in AI innovation across the product portfolio, including Academia & Government and Intellectual Property segments.
• Utilize free cash flow and proceeds from the LS&H divestiture to accelerate debt paydown.
• Focus on increasing the recurring revenue mix and enhancing customer engagement and retention.

Key Dates

Recommendation

The company is making strategic progress with its Value Creation Plan and the divestiture of a segment, which are positive long-term developments. However, the significant net loss due to a goodwill impairment charge, coupled with declining revenues and free cash flow, warrants a cautious approach. Reaffirmation of guidance provides some stability, but the impact of the impairment and ongoing revenue challenges suggest holding the stock until clearer signs of sustained organic growth and profitability improvement emerge.

Keywords

Clarivate, Q2 2026 Earnings, Financial Results, Value Creation Plan, Life Sciences & Healthcare Divestiture, Adjusted EBITDA, Organic Revenue, Goodwill Impairment